Agilent Technologies, Inc. (A) Stock Analysis
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $110.57, but acceptable to hold if already in. Reasons: Earnings in 7 days (event risk); Weak growth.
Agilent Technologies provides instruments, software, services, and consumables for laboratory workflows across life sciences, diagnostics, and applied markets through three segments globally, with approximately 18,100 employees. Revenue is earned from pharmaceutical,... Read more
Hold if already holding. Not a fresh buy at $110.57, but acceptable to hold if already in. Reasons: Earnings in 7 days (event risk); Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 5.3/10, moderate confidence.
Passes 5/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 7d<=7d. Suitability: moderate.
Recent Developments — Agilent Technologies, Inc.
Material events (past 30 days)
- May 4, 2026 MEDIUM Item 5.02: Bret DiMarco resigned as SVP, Chief Legal Officer and Secretary effective May 4, 2026; Michael Buckner appointed as new CLO same date. DiMarco to remain as Special Advisor through December 1, 2026. Clean handoff.
Latest news
- Evercore ISI Group Maintains Outperform on Agilent Technologies, Lowers Price Target to $140 — benzinga Apr 6, 2026 positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-05-04Item 5.02MEDIUMBret DiMarco resigned as SVP, Chief Legal Officer and Secretary effective May 4, 2026; Michael Buckner appointed as new CLO same date. DiMarco to remain as Special Advisor through December 1, 2026. Clean handoff.SEC filing →
- 2026-04-03Item 5.02MEDIUMBret DiMarco (CLO) entered transition agreement March 31, 2026; will resign upon new CLO appointment or September 30, 2026. No successor named at time of filing.SEC filing →
- 2026-03-06Item 5.02LOWRodney Gonsalves (VP Corporate Controller and PAO) notified Agilent of retirement effective January 2027. No successor named; departure not related to any disagreement with the company.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $110.57, but acceptable to hold if already in. Reasons: Earnings in 7 days (event risk); Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $144.96 (+31.1%), stop $106.89 (−3.4%), A.R:R 5.0:1. Score 5.3/10, moderate confidence.
Take-profit target: $144.96 (+31.1% upside). Target $144.96 (+31.1%), stop $106.89 (−3.4%), A.R:R 5.0:1. Stop-loss: $106.89.
Earnings in 7 days (event risk); Weak growth; Negative momentum.
Agilent Technologies, Inc. trades at a P/E of 24.4 (forward 16.8). TrendMatrix value score: 6.4/10. Verdict: Hold.
28 analysts cover A with a consensus score of 4.0/5. Average price target: $161.
What does Agilent Technologies, Inc. do?Agilent Technologies provides instruments, software, services, and consumables for laboratory workflows across life...
Agilent Technologies provides instruments, software, services, and consumables for laboratory workflows across life sciences, diagnostics, and applied markets through three segments globally, with approximately 18,100 employees. Revenue is earned from pharmaceutical, biopharmaceutical, academic, government, chemicals, food, and environmental customers via direct sales, distributors, and resellers.